logo
Plus   Neg
Share
Email

FCA US: Ram Truck's All-new 2019 Ram 1500 Pickup Price Starts At $31,695

FCA US LLC, a subsidiary of Fiat Chrysler Automobiles N.V. (FCAU), announced Tuesday that Ram Truck priced the all-new 2019 Ram 1500 pickup truck.

In a statement, the company said the 2019 Ram 1500 pickup truck will have a starting Manufacturer's Suggested Retail Price of $31,695 plus $1,645 destination fee.

The announcement comes as the 2019 Ram 1500, built at FCA's Sterling Heights (Michigan) Assembly Plant, is being shipped to dealers.

The all-new 2019 Ram 1500 is available in a wide range of offerings, from the well-equipped Tradesman Quad Cab 4x2's $31,695 MSRP to the technology-leading Limited Crew Cab 4x4 V-8 with standard 12-inch Uconnect touchscreen at $57,390 plus destination.

Mike Manley, Head of Ram Truck Brand - FCA, said, "In launching the all-new 2019 Ram 1500, we knew it was important to offer class-leading features and technology. But it's also important to offer our great product at a competitive price. We feel that we've delivered the right no-compromise mix that Ram Truck customers will appreciate."
The

The 2019 Ram 1500 made its worldwide debut at the North American International Auto Show in Detroit in January.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT